Stefania Merighi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7583000/publications.pdf

Version: 2024-02-01

123 papers	7,899 citations	47006 47 h-index	60623 81 g-index
127 all docs	127 docs citations	127 times ranked	6237 citing authors

#	Article	IF	Citations
1	A_{2A} Adenosine Receptor Antagonists in Neurodegenerative Diseases. Current Medicinal Chemistry, 2022, 29, 4138-4151.	2.4	18
2	Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets. International Journal of Molecular Sciences, 2022, 23, 1219.	4.1	20
3	Pathophysiological Role and Medicinal Chemistry of A2A Adenosine Receptor Antagonists in Alzheimerâ€™s Disease. Molecules, 2022, 27, 2680.	3.8	17
4	Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling. Frontiers in Cell and Developmental Biology, 2022, 10, .	3.7	0
5	A2A Adenosine Receptor: A Possible Therapeutic Target for Alzheimerâ€™s Disease by Regulating NLRP3 Inflammasome Activity?. International Journal of Molecular Sciences, 2022, 23, 5056.	4.1	9
6	Therapeutic Potential of Allicin and Aged Garlic Extract in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 6950.	4.1	21
7	An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimerâ€™s Disease Treatment?. Frontiers in Pharmacology, 2021, 12, 652455.	3.5	15
8	Upregulation of Cortical A2A Adenosine Receptors Is Reflected in Platelets of Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 80, 1105-1117.	2.6	21
9	Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?. Cells, 2021, 10, 1267.	4.1	15
10	Biological Effects on Î¼-Receptors Affinity and Selectivity of Arylpropenyl Chain Structural Modification on Diazatricyclodecane Derivatives. Molecules, 2021, 26, 5448.	3.8	1
11	A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimerâ€™s Disease. Cells, 2021, 10, 2344.	4.1	15
12	Antioxidant and Antiinflammatory Effects of Epilobium parviflorum, Melilotus officinalis and Cardiospermum halicacabum Plant Extracts in Macrophage and Microglial Cells. Cells, 2021, 10, 2691.	4.1	10
13	Signaling pathways involved in anti-inflammatory effects of Pulsed Electromagnetic Field in microglial cells. Cytokine, 2020, 125, 154777.	3.2	10
14	Synthesis, biological evaluation and docking studies of a novel class of sulfur-bridged diazabicyclo[3.3.1]nonanes. Bioorganic Chemistry, 2020, 102, 104072.	4.1	1
15	Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. Cells, 2020, 9, 2136.	4.1	26
16	A1 Adenosine Receptor Partial Agonists and Allosteric Modulators: Advancing Toward the Clinic?. Frontiers in Pharmacology, 2020, 11, 625134.	3.5	8
17	The Detrimental Action of Adenosine on Glutamate-Induced Cytotoxicity in PC12 Cells Can Be Shifted towards a Neuroprotective Role through A1AR Positive Allosteric Modulation. Cells, 2020, 9, 1242.	4.1	12
18	Adenosinergic System Involvement in Ischemic Stroke Patientsâ€™ Lymphocytes. Cells, 2020, 9, 1072.	4.1	7

#	Article	IF	Citations
19	Targeting A3 and A2A adenosine receptors in the fight against cancer. Expert Opinion on Therapeutic Targets, 2019, 23, 669-678.	3.4	32
20	Pulsed electromagnetic field and relief of hypoxiaâ€induced neuronal cell death: The signaling pathway. Journal of Cellular Physiology, 2019, 234, 15089-15097.	4.1	25
21	Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinoneâ€Based Cannabinoid Receptor Typeâ€...2 Ligands. ChemMedChem, 2018, 13, 1102-1114.	3.2	1
22	A₃ Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy. Medicinal Research Reviews, 2018, 38, 1031-1072.	10.5	111
23	Adenosine Receptors and Current Opportunities to Treat Cancer. , 2018, , 543-555.		7
24	Adenosine Receptors: Structure, Distribution, and Signal Transduction. , 2018, , 33-57.		11
25	Pharmacology of Adenosine Receptors: The State of the Art. Physiological Reviews, 2018, 98, 1591-1625.	28.8	495
26	Adenosine Receptors: The Status of the Art. , 2018, , 1-11.		2
27	Pathological overproduction: the bad side of adenosine. British Journal of Pharmacology, 2017, 174, 1945-1960.	5.4	94
28	Deregulation of Adenosine Receptors in Psoriatic Epidermis: An Option for Therapeutic Treatment. Journal of Investigative Dermatology, 2017, 137, 11-13.	0.7	12
29	A 2B adenosine receptors stimulate IL-6 production in primary murine microglia through p38 MAPK kinase pathway. Pharmacological Research, 2017, 117, 9-19.	7.1	57
30	Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists. Medicinal Research Reviews, 2017, 37, 936-983.	10.5	99
31	Biochemical and Pharmacological Role of A1 Adenosine Receptors and Their Modulation as Novel Therapeutic Strategy. Advances in Experimental Medicine and Biology, 2017, 1051, 193-232.	1.6	40
32	Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuronâ€Like and Microglial Cells. Journal of Cellular Physiology, 2017, 232, 1200-1208.	4.1	55
33	Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455. Frontiers in Pharmacology, 2017, 8, 888.	3.5	48
34	Role and Function of A2A and A3 Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis. International Journal of Molecular Sciences, 2017, 18, 697.	4.1	46
35	Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields. Mediators of Inflammation, 2017, 2017, 1-11.	3.0	63
36	The Role of Adenosine Receptors in Psychostimulant Addiction. Frontiers in Pharmacology, 2017, 8, 985.	3.5	68

#	Article	IF	Citations
37	Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?. Trends in Pharmacological Sciences, 2016, 37, 419-434.	8.7	238
38	Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1- f][1,6]naphthyridines as CB 2 receptor antagonists/inverse agonists. Bioorganic and Medicinal Chemistry, 2016, 24, 5291-5301.	3.0	15
39	Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety. Neuropharmacology, 2016, 111, 283-292.	4.1	33
40	The activation of Î¼â€opioid receptor potentiates LPSâ€induced NFâ€kB promoting an inflammatory phenotype in microglia. FEBS Letters, 2016, 590, 2813-2826.	2.8	74
41	A_{2a} and a_{2b} adenosine receptors affect HIFâ€1Î± signaling in activated primary microglial cells. Glia, 2015, 63, 1933-1952.	4.9	39
42	Adenosine receptors and diabetes: Focus on the A2B adenosine receptor subtype. Pharmacological Research, 2015, 99, 229-236.	7.1	36
43	PKCÎµ as a novel promoter of skeletal muscle differentiation and regeneration. Experimental Cell Research, 2015, 339, 10-19.	2.6	17
44	The A₃Adenosine Receptor: History and Perspectives. Pharmacological Reviews, 2015, 67, 74-102.	16.0	204
45	Synthesis and Biological Evaluation of Pyrazolo[3,4-<i>b</i>]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors. Medicinal Chemistry, 2015, 11, 342-353.	1.5	6
46	Targeting adenosine receptors to prevent inflammatory skin diseases. Experimental Dermatology, 2014, 23, 553-554.	2.9	8
47	TRR469, a potent A1 adenosine receptor allosteric modulator, exhibits anti-nociceptive properties in acute and neuropathic pain models in mice. Neuropharmacology, 2014, 81, 6-14.	4.1	59
48	Morphine mediates a proinflammatory phenotype via Î¼-opioid receptorâ€“PKCÉ›â€“Aktâ€“ERK1/2 signaling pathway in activated microglial cells. Biochemical Pharmacology, 2013, 86, 487-496.	4.4	98
49	A1 and A3 adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes. Pharmacological Research, 2013, 76, 157-170.	7.1	44
50	Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models. Pain, 2013, 154, 864-873.	4.2	56
51	Multiple sclerosis lymphocytes upregulate <scp>A</scp>_{2A} adenosine receptors that are antiinflammatory when stimulated. European Journal of Immunology, 2013, 43, 2206-2216.	2.9	45
52	A2A Adenosine Receptors Are Differentially Modulated by Pharmacological Treatments in Rheumatoid Arthritis Patients and Their Stimulation Ameliorates Adjuvant-Induced Arthritis in Rats. PLoS ONE, 2013, 8, e54195.	2.5	43
53	Pulsed Electromagnetic Fields Increased the Anti-Inflammatory Effect of A2A and A3 Adenosine Receptors in Human T/C-28a2 Chondrocytes and hFOB 1.19 Osteoblasts. PLoS ONE, 2013, 8, e65561.	2.5	106
54	Cannabinoid CB₂ receptor attenuates morphineâ€induced inflammatory responses in activated microglial cells. British Journal of Pharmacology, 2012, 166, 2371-2385.	5.4	69

#	Article	IF	Citations
55	Downregulation of A1 and A2B adenosine receptors in human trisomy 21 mesenchymal cells from first-trimester chorionic villi. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1660-1670.	3.8	9
56	Hydrogen sulfide modulates the release of nitric oxide and VEGF in human keratinocytes. Pharmacological Research, 2012, 66, 428-436.	7.1	35
57	Water-Soluble Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as Human A₃ Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2012, 55, 5380-5390.	6.4	11
58	The Anti-Tumor Effect of A3 Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells. PLoS ONE, 2012, 7, e39317.	2.5	39
59	Adenosine receptor targeting in health and disease. Expert Opinion on Investigational Drugs, 2011, 20, 1591-1609.	4.1	74
60	Adenosine receptors and cancer. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1400-1412.	2.6	186
61	Synthesis and biological activity of a novel class nicotinic acetylcholine receptors (nAChRs) ligands structurally related to anatoxin-a. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5423-5427.	2.2	4
62	Adenosine Receptors in Health and Disease. Advances in Pharmacology, 2011, 61, 41-75.	2.0	70
63	Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors. Biochemical Pharmacology, 2010, 79, 471-477.	4.4	22
64	Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. Biochemical Pharmacology, 2010, 79, 1483-1495.	4.4	63
65	Adenosine Modulates HIF-1Î±, VEGF, IL-8, and Foam Cell Formation in a Human Model of Hypoxic Foam Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 90-97.	2.4	71
66	Allosteric Enhancers of A1 Adenosine Receptors: State of the Art and New Horizons for Drug Development. Current Medicinal Chemistry, 2010, 17, 3488-3502.	2.4	41
67	Glucocorticoids Pharmacology: Past, Present and Future. Current Pharmaceutical Design, 2010, 16, 3540-3553.	1.9	26
68	Thermodynamic Analysis in Drugâ€“Receptor Binding: The A3 Adenosine Receptor. , 2010, , 29-48.		0
69	Agonists and Antagonists: Molecular Mechanisms and Therapeutic Applications. , 2010, , 301-317.		3
70	Regulation of Second Messenger Systems and Intracellular Pathways. , 2010, , 61-73.		5
71	A2B and A3 Adenosine Receptors Modulate Vascular Endothelial Growth Factor and Interleukin-8 Expression in Human Melanoma Cells Treated with Etoposide and Doxorubicin. Neoplasia, 2009, 11, 1064-1073.	5.3	66
72	Thermodynamics of A2B adenosine receptor binding discriminates agonistic from antagonistic behaviour. Biochemical Pharmacology, 2008, 75, 562-569.	4.4	17

#	Article	IF	Citations
73	Binding thermodynamic characterization of human P2X1 and P2X3 purinergic receptors. Biochemical Pharmacology, 2008, 75, 1198-1208.	4.4	9
74	Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields. Osteoarthritis and Cartilage, 2008, 16, 292-304.	1.3	110
75	Pharmacological characterization of P2X1 and P2X3 purinergic receptors in bovine chondrocytes. Osteoarthritis and Cartilage, 2008, 16, 1421-1429.	1.3	39
76	The A3 adenosine receptor: An enigmatic player in cell biology. , 2008, 117, 123-140.		197
77	Caffeine Inhibits Adenosine-Induced Accumulation of Hypoxia-Inducible Factor-1Î±, Vascular Endothelial Growth Factor, and Interleukin-8 Expression in Hypoxic Human Colon Cancer Cells. Molecular Pharmacology, 2007, 72, 395-406.	2.3	149
78	Hypoxia Inhibits Paclitaxel-Induced Apoptosis through Adenosine-Mediated Phosphorylation of Bad in Glioblastoma Cells. Molecular Pharmacology, 2007, 72, 162-172.	2.3	74
79	Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: Focus on the A3 adenosine subtype. Journal of Cellular Physiology, 2007, 211, 826-836.	4.1	107
80	Adenosine and lymphocyte regulation. Purinergic Signalling, 2007, 3, 109-116.	2.2	71
81	Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors. Purinergic Signalling, 2006, 2, 583-588.	2.2	6
82	Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A3 adenosine receptor. Purinergic Signalling, 2006, 2, 627-632.	2.2	30
83	Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochemical Pharmacology, 2006, 72, 19-31.	4.4	110
84	Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochemical Pharmacology, 2005, 70, 1601-1612.	4.4	53
85	Synthesis and Biological Evaluation of Allosteric A1-Adenosine Receptor Modulators Structurally Related to (2-Amino-4,5,6,7-Tetrahydro-Benzo[B]Thiophen-3-YL)-(4-Chloro-Phenyl)-Methanone, a Potent Compound Useful to Reduce Neuropathic Pain. Medicinal Chemistry Research, 2005, 14, 125-142.	2.4	4
86	Pyrazolo[4,3-e]1,2,4-Triazolo[1,5-c]Pyrimidine Ligands, New Tools to Characterize A3 Adenosine Receptors in Human Tumor Cell Lines. Current Medicinal Chemistry, 2005, 12, 1319-1329.	2.4	35
87	A3 Adenosine Receptor Activation Inhibits Cell Proliferation via Phosphatidylinositol 3-Kinase/Akt-dependent Inhibition of the Extracellular Signal-regulated Kinase 1/2 Phosphorylation in A375 Human Melanoma Cells. Journal of Biological Chemistry, 2005, 280, 19516-19526.	3.4	106
88	Expression, Pharmacological Profile, and Functional Coupling of A2B Receptors in a Recombinant System and in Peripheral Blood Cells Using a Novel Selective Antagonist Radioligand, [3H]MRE 2029-F20. Molecular Pharmacology, 2005, 67, 2137-2147.	2.3	58
89	Synthesis and Pharmacology of 6-Substituted Benztropines:Â Discovery of Novel Dopamine Uptake Inhibitors Possessing Low Binding Affinity to the Dopamine Transporter. Journal of Medicinal Chemistry, 2005, 48, 3337-3343.	6.4	10
90	New Pyrrolo[2,1-f]purine-2,4-dione and Imidazo[2,1-f]purine-2,4-dione Derivatives as Potent and Selective Human A3Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2005, 48, 4697-4701.	6.4	45

#	Article	IF	Citations
91	A3 Adenosine Receptors Modulate Hypoxia-inducible Factor-1a Expression in Human A375 Melanoma Cells. Neoplasia, 2005, 7, 894-903.	5.3	77
92	Expression of A3Adenosine Receptors in Human Lymphocytes: Up-Regulation in T Cell Activation. Molecular Pharmacology, 2004, 65, 711-719.	2.3	86
93	[3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3607-3610.	2.2	35
94	Design, Synthesis, and Biological Evaluation of New 8-Heterocyclic Xanthine Derivatives as Highly Potent and Selective Human A2BAdenosine Receptor Antagonists. Journal of Medicinal Chemistry, 2004, 47, 1434-1447.	6.4	359
95	Receptor Binding Thermodynamics at the Neuronal Nicotinic Receptor. Current Topics in Medicinal Chemistry, 2004, 4, 361-368.	2.1	20
96	Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine. Biochemical Pharmacology, 2003, 66, 739-748.	4.4	281
97	Alteration of A3 adenosine receptors in human neutrophils and low frequency electromagnetic fields. Biochemical Pharmacology, 2003, 66, 1897-1906.	4.4	28
98	A glance at adenosine receptors: novel target for antitumor therapy. , 2003, 100, 31-48.		440
99	Recent developments in the field of A3 adenosine receptor antagonists. Drug Development Research, 2003, 58, 315-329.	2.9	28
100	Adenosine receptors and human melanoma. Drug Development Research, 2003, 58, 377-385.	2.9	10
101	Synthesis and Biological Effects of Novel 2-Amino-3-naphthoylthiophenes as Allosteric Enhancers of the A1Adenosine Receptor. Journal of Medicinal Chemistry, 2003, 46, 794-809.	6.4	48
102	Design, Synthesis, and Biological Evaluation of C9- and C2-Substituted Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as New A2Aand A3Adenosine Receptors Antagonists. Journal of Medicinal Chemistry, 2003, 46, 1229-1241.	6.4	70
103	A₃Adenosine Receptors in Human Neutrophils and Promyelocytic HL60 Cells: A Pharmacological and Biochemical Study. Molecular Pharmacology, 2002, 61, 415-424.	2.3	375
104	Binding thermodynamics at the human A3 adenosine receptor. Biochemical Pharmacology, 2002, 63, 157-161.	4.4	25
105	Adenosine Receptors as Mediators of Both Cell Proliferation and Cell Death of Cultured Human Melanoma Cells. Journal of Investigative Dermatology, 2002, 119, 923-933.	0.7	134
106	Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. British Journal of Pharmacology, 2002, 136, 57-66.	5.4	119
107	Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 823-827.	2.2	15
108	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new pharmacological tool for the characterization of the human A3 adenosine receptor. Drug Development Research, 2001, 52, 406-415.	2.9	10

#	Article	IF	Citations
109	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor ligands: A starting point for searching A2B adenosine receptor antagonists. Drug Development Research, 2001, 53, 225-235.	2.9	21
110	Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. British Journal of Pharmacology, 2001, 134, 116-126.	5.4	100
111	Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. British Journal of Pharmacology, 2001, 134, 1215-1226.	5.4	107
112	A3 Adenosine Receptor Ligands: History and Perspectives. , 2000, 20, 103-128.		130
113	Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 209-211.	2.2	22
114	Synthesis and activity of 3-pyridylamine ligands at central nicotinic receptors. European Journal of Medicinal Chemistry, 2000, 35, 979-988.	5.5	31
115	A2A adenosine receptors in human peripheral blood cells. British Journal of Pharmacology, 2000, 129, 2-11.	5.4	145
116	Synthesis and Binding of 3-Aminopyridine Derivatives at Central Nicotinic Receptors. Arzneimittelforschung, 2000, 50, 507-511.	0.4	0
117	Dose and Time Effects of Caffeine Intake on Human Platelet Adenosine A _{2A} Receptors. Circulation, 2000, 102, 285-289.	1.6	104
118	Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptor Antagonists:Â Influence of the Chain at the N8Pyrazole Nitrogen. Journal of Medicinal Chemistry, 2000, 43, 4768-4780.	6.4	89
119	Caffeine Alters A _{2A} Adenosine Receptors and Their Function in Human Platelets. Circulation, 1999, 99, 2499-2502.	1.6	102
120	Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptor Antagonists. Journal of Medicinal Chemistry, 1999, 42, 4473-4478.	6.4	80
121	Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships. British Journal of Pharmacology, 1998, 125, 1485-1490.	5.4	37
122	Adenosine A2A receptors of human circulating blood elements. Drug Development Research, 1998, 45, 253-260.	2.9	5
123	Temporal Mapping of Transcripts in Herpesvirus 6 Variants. Journal of Virology, 1998, 72, 3837-3844.	3.4	80